Security
Cytokinetics, Incorporated Common Stock · CYTK
CYTKNASDAQCommon stockCurrentCIK 1061983Updated Nov 3, 2026
CYTK price & chart
Loading TradingView…
NASDAQ:CYTK on TradingView ↗About the company
Cytokinetics is a specialty cardiovascular biopharmaceutical company, building on its over 25 years of pioneering scientific innovations in muscle biology, and advancing a pipeline of potential new medicines for patients suffering from diseases of cardiac muscle dysfunction. Cytokinetics’ MYQORZO® (aficamten) is a cardiac myosin inhibitor approved in the approved in the U.S., China, European Union and United Kingdom for the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM). Following positive results in ACACIA-HCM, a Phase 3 clinical trial of aficamten in patients with non-obstructive HCM (nHCM), the company plans to submit a Supplemental New Drug Application in Q4 2026. Cytokinetics is also developing omecamtiv mecarbil, an investigational cardiac myosin activator for the potential treatment of patients with heart failure with severely reduced ejection fraction and ulacamten, an investigational cardiac myosin inhibitor for the potential treatment of heart failure with preserved ejection fraction, while continuing pre-clinical research and development in muscle biology.
In the news
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) ↗
CYTK Deadline: CYTK Investors Have Opportunity to Lead Cytokinetics, Inc. Securities Fraud Lawsuit News provided by THE ROSEN LAW FIRM, P. A. Nov 17, 2025, 19:39 ET Share this article Share to X Share this article Share to X NEW YORK , Nov. 17, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global inve ↗
The Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of Cytokinetics, Incorporated (CYTK) Shareholders News provided by The Gross Law Firm Nov 17, 2025, 08:45 ET Share this article Share to X Share this article Share to X NEW YORK , Nov. 17, 2025 /PRNewswire/ -- The Gross L ↗
Recent filings
144 filing
144 filing
4 filing
4 filing
Other Events
Items 8.01, 9.01
Show 5 more recent filings
4 filing
Other Events
Items 8.01
10-Q filing
Results of Operations and Financial Condition
Items 2.02, 9.01
4 filing
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 1,436,557,000Source | 1,436,060,000Source | 1,924,551,000Source | 1,225,635,000Source | 1,523,788,000Source | 1,273,478,000Source | 1,264,051,000Source | 808,082,000Source | 1,424,537,000Source | 1,401,673,000Source | 824,316,000Source | 1,014,775,000Source |
| Property, Plant and Equipment, NetUSD | 76,001,000Source | 64,222,000Source | 78,916,000Source | 70,219,000Source | 65,689,000Source | 82,438,000Source | 67,175,000Source | 68,018,000Source | 79,194,000Source | 65,815,000Source | 68,748,000Source | 80,453,000Source |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 225,467,000Source | 46,888,000Source | 255,271,000Source | 74,940,000Source | 190,142,000Source | 129,843,000Source | 73,680,000Source | 119,976,000Source | 122,518,000Source | 94,857,000Source | 113,024,000Source | 65,582,000Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 1,808,000Source | 244,000Source | 24,432,000Source | 8,410,000Source | 0Source | 6,827,000Source | 2,012,000Source | 834,000Source | 17,764,000Source | 16,650,000Source | 1,283,000Source | 147,000Source |
| Assets, CurrentUSD | 977,349,000Source | 1,018,601,000Source | 1,208,487,000Source | 886,542,000Source | 1,067,810,000Source | 839,465,000Source | 956,053,000Source | 638,704,000Source | 916,975,000Source | 1,107,940,000Source | 628,051,000Source | 795,186,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 13,006,000Source | 6,665,000Source | 17,989,000Source | 19,997,000Source | 11,035,000Source | 13,934,000Source | 15,823,000Source | 18,909,000Source | 16,990,000Source | 15,276,000Source | 11,944,000Source | 12,462,000Source |
| Operating Lease, Right-of-Use AssetUSD | 77,580,000Source | 76,344,000Source | 72,896,000Source | 76,120,000Source | 77,249,000Source | 74,545,000Source | 77,439,000Source | 78,170,000Source | 75,979,000Source | 75,158,000Source | 78,987,000Source | 82,737,000Source |
| Other Assets, NoncurrentUSD | 16,810,000Source | 7,725,000Source | 19,406,000Source | 14,553,000Source | 7,679,000Source | 18,468,000Source | 12,697,000Source | 7,814,000Source | 17,341,000Source | 7,705,000Source | 7,996,000Source | 9,691,000Source |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 1,957,680,000Source | 1,449,971,000Source | 2,098,038,000Source | 1,594,355,000Source | 1,415,238,000Source | 2,100,046,000Source | 1,530,464,000Source | 1,204,242,000Source | 2,084,162,000Source | 1,537,045,000Source | 1,210,639,000Source | 1,122,675,000Source |
| Stockholders’ equity: | ||||||||||||
| Preferred Stock, Value, IssuedUSD | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source |
| Common Stock, Value, IssuedUSD | 122,000Source | 118,000Source | 138,000Source | 119,000Source | 117,000Source | 124,000Source | 119,000Source | 105,000Source | 123,000Source | 118,000Source | 102,000Source | 94,000Source |
| Retained Earnings (Accumulated Deficit)USD | -3,303,688,000Source | -2,551,744,000Source | -3,891,512,000Source | -2,997,510,000Source | -2,391,199,000Source | -3,692,750,000Source | -2,863,140,000Source | -2,247,881,000Source | -3,486,719,000Source | -2,701,764,000Source | -2,112,238,000Source | -1,585,994,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 34,000Source | 5,387,000Source | -3,826,000Source | -158,000Source | -1,022,000Source | -1,612,000Source | 1,545,000Source | -539,000Source | 630,000Source | 2,398,000Source | -10,000Source | -3,590,000Source |
| Stockholders' Equity Attributable to ParentUSD | -521,123,000Source | -13,911,000Source | -173,487,000Source | -368,720,000Source | 108,550,000Source | -826,568,000Source | -266,413,000Source | -396,160,000Source | -659,625,000Source | -135,372,000Source | -386,323,000Source | -107,900,000Source |
| Additional Paid in Capital, Common StockUSD | 2,782,409,000Source | 2,532,328,000Source | 3,721,713,000Source | 2,628,829,000Source | 2,500,654,000Source | 2,867,670,000Source | 2,595,063,000Source | 1,852,155,000Source | 2,826,341,000Source | 2,563,876,000Source | 1,725,823,000Source | 1,481,590,000Source |
| Liabilities and EquityUSD | 1,436,557,000Source | 1,436,060,000Source | 1,924,551,000Source | 1,225,635,000Source | 1,523,788,000Source | 1,273,478,000Source | 1,264,051,000Source | 808,082,000Source | 1,424,537,000Source | 1,401,673,000Source | 824,316,000Source | 1,014,775,000Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 142,144,000Source | 109,812,000Source | 181,429,000Source | 131,064,000Source | 102,777,000Source | 199,185,000Source | 159,726,000Source | 88,855,000Source | 202,452,000Source | 179,674,000Source | 102,678,000Source | 84,617,000Source |
| Operating Lease, Liability, CurrentUSD | 20,647,000Source | 18,856,000Source | 21,042,000Source | 19,585,000Source | 18,507,000Source | 20,960,000Source | 19,574,000Source | 18,230,000Source | 19,111,000Source | 18,978,000Source | 17,891,000Source | 12,829,000Source |
| Accounts Payable, CurrentUSD | 22,084,000Source | 11,581,000Source | 20,510,000Source | 16,228,000Source | 9,470,000Source | 24,709,000Source | 13,942,000Source | 12,967,000Source | 22,337,000Source | 20,369,000Source | 21,507,000Source | 25,611,000Source |
| Operating Lease, Liability, NoncurrentUSD | 110,655,000Source | 114,752,000Source | 102,426,000Source | 111,028,000Source | 116,718,000Source | 105,235,000Source | 113,353,000Source | 118,554,000Source | 107,970,000Source | 112,582,000Source | 120,427,000Source | 126,895,000Source |
| Other Liabilities, NoncurrentUSD | 1,612,000Source | 0Source | — | 2,015,000Source | 0Source | — | 2,821,000Source | 2,000Source | — | 0Source | 186,000Source | 1,044,000Source |
| Additional Financial Items | ||||||||||||
| Accrued Liabilities, CurrentUSD | 61,633,000Source | 49,826,000Source | 76,862,000Source | 52,315,000Source | 39,813,000Source | 68,863,000Source | 43,358,000Source | 40,123,000Source | 83,278,000Source | 55,323,000Source | 42,641,000Source | 44,096,000Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | 1,300,000,000Source | 1,300,000,000Source | 1,700,000,000Source | 1,000,000,000Source | 1,400,000,000Source | 1,100,000,000Source | 1,100,000,000Source | 634,300,000Source | 1,200,000,000Source | 1,221,100,000Source | 655,400,000Source | 829,300,000Source |
| Deferred Revenue, CurrentUSD | 1,612,000Source | — | 1,653,000Source | 1,344,000Source | — | 1,653,000Source | 52,370,000Source | — | 1,612,000Source | 52,370,000Source | — | — |
| Deferred Revenue, NoncurrentUSD | — | — | — | — | — | — | — | — | — | — | — | 0Source |
| Long-term Debt, Current MaturitiesUSD | 17,280,000Source | 11,520,000Source | 27,358,000Source | 14,400,000Source | 11,520,000Source | 44,808,000Source | 12,960,000Source | 11,520,000Source | 41,181,000Source | 11,520,000Source | 10,080,000Source | — |
| Long-term Debt, Excluding Current MaturitiesUSD | 158,747,000Source | 93,017,000Source | 248,202,000Source | 159,058,000Source | 92,831,000Source | 247,209,000Source | 92,025,000Source | 56,822,000Source | 246,384,000Source | 93,227,000Source | 58,384,000Source | 63,810,000Source |
| Inventory, Net | — | — | —Source | — | — | —Source | — | — | — | — | — | — |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | — | — | — | — | — | — | -206,031,000Source | -161,376,000Source | -784,955,000Source | -589,526,000Source | -526,244,000Source | -388,955,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Depreciation, Depletion and AmortizationUSD | — | — | — | — | — | — | 3,378,000Source | 2,300,000Source | 10,125,000Source | 9,531,000Source | 11,892,000Source | 5,814,000Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | 30,394,000Source | 23,549,000Source | 112,286,000Source | 97,840,000Source | 72,065,000Source | 47,853,000Source |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts ReceivableUSD | — | — | — | — | — | — | -10,937,000Source | -14,638,000Source | 1,114,000Source | 15,367,000Source | 1,136,000Source | -56,672,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -145,457,000Source | -131,617,000Source | -510,009,000Source | -395,890,000Source | -414,333,000Source | -299,516,000Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | 145,492,000Source | 105,956,000Source | 16,666,000Source | -553,097,000Source | 239,253,000Source | -262,134,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | 5,930,000Source | 5,664,000Source | 24,807,000Source | 3,906,000Source | 1,416,000Source | 11,335,000Source |
| Cash flows from financing activities: | ||||||||||||
| Payment, Tax Withholding, Share-based Payment ArrangementUSD | — | — | — | — | — | — | 841,000Source | 13,000Source | 2,468,000Source | 19,631,000Source | 10,517,000Source | 9,602,000Source |
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | 7,770,000Source | 4,754,000Source | 524,458,000Source | 930,611,000Source | 221,317,000Source | 516,166,000Source |
| Repayments of Long-term DebtUSD | — | — | — | — | — | — | 2,735,000Source | 2,682,000Source | 10,809,000Source | 8,679,000Source | — | 47,651,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | 7,322,000Source | -21,177,000Source | 30,400,000Source | -18,167,000Source | 46,217,000Source | -45,484,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | 228,579,000Source | — | 258,378,000Source | 76,551,000Source | 132,954,000Source | 74,055,000Source | 125,632,000Source | 95,232,000Source | 113,399,000Source | 67,182,000Source |
| Supplemental disclosure of cash flow information: | ||||||||||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | — | — | — | — | — | — | 1,585,000Source | 9,647,000Source | 22,914,000Source | 25,970,000Source | 10,295,000Source | 15,165,000Source |
| Income Taxes Paid, NetUSD | — | — | — | — | — | — | — | — | 0Source | — | — | — |
| Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | — | — | — | — | -483,000Source | -270,000Source | -715,000Source | 209,000Source | -20,000Source | — |
| Additional Financial Items | ||||||||||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | 30,696,000Source | 25,356,000Source | 35,711,000Source | 27,535,000Source | 30,394,000Source | 23,549,000Source | 112,286,000Source | 97,840,000Source | 72,065,000Source | 47,853,000Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | — | — | 1,300,000,000Source | 1,300,000,000Source | 1,700,000,000Source | 1,000,000,000Source | 1,100,000,000Source | 1,100,000,000Source | 1,200,000,000Source | 1,221,100,000Source | 655,400,000Source | 829,300,000Source |
| DepreciationUSD | — | — | — | — | — | — | — | — | 10,100,000Source | 9,500,000Source | 11,900,000Source | 5,800,000Source |
| Derivative, Gain (Loss) on Derivative, NetUSD | — | — | 700,000Source | 700,000Source | -1,100,000Source | 3,000,000Source | 1,500,000Source | -400,000Source | 4,200,000Source | 1,300,000Source | — | — |
| Gain (Loss) on Sale of InvestmentsUSD | — | — | — | — | — | — | — | — | — | — | -35,000Source | -107,000Source |
| Gain (Loss) on Extinguishment of DebtUSD | — | — | — | — | — | — | — | — | — | 0Source | — | -2,693,000Source |
| General and Administrative ExpenseUSD | — | — | 69,458,000Source | 56,652,000Source | — | 65,721,000Source | — | 57,369,000Source | 284,271,000Source | 215,314,000Source | 173,612,000Source | 177,977,000Source |
| Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 0Source | 0Source | 0Source | 0Source |
| Investment Income, InterestUSD | — | — | — | — | — | — | — | — | — | — | — | 11,400,000Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -306,178,000Source | -160,545,000Source | -198,762,000Source | -134,370,000Source | -206,031,000Source | -161,376,000Source | -784,955,000Source | -589,526,000Source | -526,244,000Source | -388,955,000Source |
| Nonoperating Income (Expense)USD | — | — | 10,248,000Source | 17,054,000Source | 13,941,000Source | 13,001,000Source | 11,022,000Source | 13,701,000Source | 48,420,000Source | 51,534,000Source | 27,629,000Source | 11,342,000Source |
| Operating ExpensesUSD | — | — | 168,691,000Source | 141,264,000Source | 207,796,000Source | 178,275,000Source | 202,973,000Source | 157,210,000Source | 700,297,000Source | 554,722,000Source | 503,735,000Source | 418,790,000Source |
| Operating Lease, Impairment LossUSD | — | — | — | — | — | — | — | — | — | — | — | 0Source |
| Proceeds from Issuance of Common StockUSD | — | — | — | — | — | — | — | 0Source | — | — | 164,233,000Source | — |
| Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-saleUSD | — | — | — | — | — | — | 257,938,000Source | 275,725,000Source | 1,103,645,000Source | 744,225,000Source | 870,905,000Source | 604,594,000Source |
| Realized Investment Gains (Losses)USD | — | — | — | — | — | — | 61,000Source | 0Source | 25,000Source | 19,000Source | — | — |
| Increase (Decrease) in Inventories | — | — | — | — | — | — | —Source | —Source | — | — | — | — |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total RevenueUSD | — | — | 1,936,000Source | 463,000Source | 28,624,000Source | 66,769,000Source | 19,355,000Source | 1,579,000Source | 88,039,000Source | 18,474,000Source | 7,530,000Source | 94,588,000Source |
| Operating Income (Loss)USD | — | — | -166,755,000Source | -140,801,000Source | -179,172,000Source | -111,506,000Source | -183,618,000Source | -155,631,000Source | -612,258,000Source | -536,248,000Source | -496,205,000Source | -324,202,000Source |
| Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 0Source | 0Source | 0Source | 0Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -306,178,000Source | -160,545,000Source | -198,762,000Source | -134,370,000Source | -206,031,000Source | -161,376,000Source | -784,955,000Source | -589,526,000Source | -526,244,000Source | -388,955,000Source |
| Earnings Per Share, BasicUSD per share | — | — | -2.55Source | -1.36Source | -1.5Source | -1.12Source | -1.67Source | -1.36Source | -6.54Source | -5.26Source | -5.45Source | -4.33Source |
| Earnings Per Share, DilutedUSD per share | — | — | -2.55Source | -1.36Source | -1.5Source | -1.12Source | -1.67Source | -1.36Source | -6.54Source | -5.26Source | -5.45Source | -4.33Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 119,982Source | 117,685Source | 132,086Source | 119,457Source | 123,273Source | 118,496Source | 120,103Source | 111,979Source | 96,524Source | 89,825Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 119,982Source | 117,685Source | 132,086Source | 119,457Source | 123,273Source | 118,496Source | 120,103Source | 111,979Source | 96,524Source | 89,825Source |
| Additional Financial Items | ||||||||||||
| General and Administrative ExpenseUSD | — | — | 69,458,000Source | 56,652,000Source | — | 65,721,000Source | — | 57,369,000Source | 284,271,000Source | 215,314,000Source | 173,612,000Source | 177,977,000Source |
| Interest ExpenseUSD | — | — | 11,353,000Source | 8,928,000Source | — | 11,084,000Source | — | — | 45,579,000Source | 37,701,000Source | 28,306,000Source | 19,414,000Source |
| Investment Income, InterestUSD | — | — | — | — | — | — | — | — | — | — | — | 11,400,000Source |
| Nonoperating Income (Expense)USD | — | — | 10,248,000Source | 17,054,000Source | 13,941,000Source | 13,001,000Source | 11,022,000Source | 13,701,000Source | 48,420,000Source | 51,534,000Source | 27,629,000Source | 11,342,000Source |
| Operating ExpensesUSD | — | — | 168,691,000Source | 141,264,000Source | 207,796,000Source | 178,275,000Source | 202,973,000Source | 157,210,000Source | 700,297,000Source | 554,722,000Source | 503,735,000Source | 418,790,000Source |
| Realized Investment Gains (Losses)USD | — | — | — | — | — | — | 61,000Source | 0Source | 25,000Source | 19,000Source | — | — |
| Research and Development ExpenseUSD | — | — | 99,233,000Source | 84,612,000Source | 97,807,000Source | 110,138,000Source | 95,525,000Source | 98,262,000Source | 416,026,000Source | 339,408,000Source | 330,123,000Source | 240,813,000Source |
| Selling, General and Administrative Expense | — | — | — | — | —Source | —Source | —Source | —Source | — | — | — | — |
Filing attachments
cytk-ex99_1.htm · 8-K · 2026-08-28
EX-99.1 2 cytk-ex99_1.htm EX-99.1 EX-99.1 Cytokinetics Announces Positive Results from ACACIA-HCM Presented in Hot Line Session at the European Society of Cardiology (ESC) Congress 2026 and Published in The New England Journal of Medicine ACACIA-HCM is the First Phase 3 Clinical Trial to Successfully Demonstrate Statistically Significant Improvements Across Both Patient-Reported and Physician-Assessed Endpoints in Non-Obstructive HCM Supplemental New Drug Application to be Submitted to F…
Read attachment ↗cytk-ex99_1.htm · 8-K · 2026-08-06
EX-99.1 2 cytk-ex99_1.htm EX-99.1 EX-99.1 Cytokinetics Reports Second Quarter 2026 Financial Results and Provides Business Update MYQORZO® (aficamten) Net Product Revenue of $25 Million Full Results from ACACIA-HCM to be Presented in Hot Line Session at ESC; Expect to Submit Supplemental NDA for Aficamten in Non-Obstructive HCM in Q4 2026 MYQORZO Launched in Germany, Approved in United Kingdom and Regulatory Review Ongoing in Canada, Switzerland, Hong Kong and Taiwan ~$1.7 Billion in …
Read attachment ↗d124879dex991.htm · 8-K · 2026-05-05
EX-99.1 2 d124879dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 1 Forward-Looking Statements This presentation contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the “Act”). Cytokinetics disclaims any intent or obligation to update these forward-looking statements and claims the protection of the Act's safe harbor for forward-looking statements. Examples of such statements include, but are not limited to, statements, express or implied, relat…
Read attachment ↗cytk-ex99_1.htm · 8-K · 2026-05-05
EX-99.1 2 cytk-ex99_1.htm EX-99.1 EX-99.1 Cytokinetics Reports First Quarter 2026 Financial Results and Provides Business Update U.S. Launch of MYQORZO® (aficamten) in Late January Met with Strong Demand; Over 275 HCPs Prescribed MYQORZO to an estimated 680 Patients in Q1 ACACIA-HCM Met Dual Primary Endpoints of KCCQ and Maximal Exercise Performance; Full Results to be Presented at Upcoming Medical Congress MYQORZO Approved by the European Commission for Adults with Symptomatic Obstruc…
Read attachment ↗cytk-ex99_1.htm · 8-K · 2026-02-24
EX-99.1 2 cytk-ex99_1.htm EX-99.1 EX-99.1 Cytokinetics Reports Fourth Quarter 2025 Financial Results and Provides Business Update MYQORZO® Approved for Adults with Symptomatic Obstructive HCM in U.S., China and Europe; U.S. Launch Underway with First Prescriptions Dispensed within Days of Drug Availability Supplemental NDA for MAPLE-HCM Submitted to FDA in Q1 2026 Expect to Share Topline Results from ACACIA-HCM in Q2 2026 Company Provides 2026 Financial Guidance; ~$1.2 Billion in Cash…
Read attachment ↗cytk-ex99_1.htm · 8-K · 2025-11-05
EX-99.1 2 cytk-ex99_1.htm EX-99.1 EX-99.1 CYTOKINETICS REPORTS THIRD QUARTER 2025 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE Interactions with FDA Progressing Towards December 26, 2025 PDUFA Date for Aficamten; U.S. Commercial Launch Preparations on Track Ex-U.S. Regulatory Reviews of Aficamten Ongoing in China and E.U. ~$1.25 Billion in Cash, Cash Equivalents and Investments as of September 30, 2025 SOUTH SAN FRANCISCO, Calif., Nov. 5, 2025 - Cytokinetics, Incorporated (Nasdaq: CY…
Read attachment ↗